ACADEMIC AND RESEARCH PEER-REVIEWED MEDICAL JOURNALISSN 1727-2378 (Print)         ISSN 2713-2994 (Online)
Ru
En

Allopurinol for Treating Gout

For citation: Zhelyabina O. V., Chikina M. N., Eliseev M. S. Allopurinol for Treating Gout. Doctor.Ru. 2017. 10(139): 57–62.
20 October 00:00

Objective of the Review: To analyze the main principles of treatment with allopurinol and possible errors in administering this medication to gout patients, and to discuss how allopurinol could be used in patients with asymptomatic hyperuricemia, chronic kidney disease, or cardiovascular disorders.

Key Points: For doctors managing gout patients, the main objective is to achieve target uric acid (UA) levels and maintain them lifelong. Underdosing of allopurinol is a common reason for failure to achieve target UA levels.

Conclusion: In addition to reports of the direct uric-acid-lowering effect of xanthine oxidase inhibitors, there is increasing evidence that these medications, especially allopurinol, have other positive effects when used long-term.

O. V. Zhelyabina — V. A. Nasonova Rheumatology Research Institute, Moscow. E-mail: olga-sheliabina@mail.ru

M. N. Chikina — V. A. Nasonova Rheumatology Research Institute, Moscow. E-mail: Maria.sorokvasha@yandex.ru

M. S. Eliseev — V. A. Nasonova Rheumatology Research Institute, Moscow. E-mail: elicmax@rambler.ru

Доктор.ру
20 October 00:00
LITERATURE
  1. Насонова В. А., Барскова В. Г. Ранние диагностика и лечение подагры — научно обоснованное требование улучшения трудового и жизненного прогноза больных. Науч.-практ. ревматология. 2004; 1: 5–7. [Nasonova V. A., Barskova V. G. Rannie diagnostika i lechenie podagry — nauchno obosnovannoe trebovanie uluchsheniya trudovogo i zhiznennogo prognoza bol’nykh. Nauch.-prakt. revmatologiya. 2004; 1: 5–7. (in Russian)]
  2. Shoji A., Yamanaka H., Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004; 51(3): 321–5.
  3. Елисеев М. С. Алгоритм диагностики и лечения подагры. Рус. мед. журн. 2015; 23(7): 410–4. [Eliseev M. S. Algoritm diagnostiki i lecheniya podagry. Rus. med. zhurn. 2015; 23(7): 410–4. (in Russian)]
  4. Doherty M., Jansen T. L., Nuki G., Pascual E., Perez-Ruiz F., Punzi L. et al. Gout: why is this curable disease so seldom cured? Ann. Rheum. Dis. 2012; 71(11): 1765–70.
  5. Eminaga F., La-Crette J., Jones A., Abhishek A. Does the initiation of urate-lowering treatment during an acute gout attack prolong the current episode and precipitate recurrent attacks: a systematic literature review. Rheumatol. Int. 2016; 36(12): 1747–52.
  6. Pacher P., Nivorozhkin A., Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol. Rev. 2006; 58(1): 87–114.
  7. Richette P., Doherty M., Pascual E., Barskova V., Becce F., Castañeda-Sanabria J. et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann. Rheum. Dis. 2017; 76(1): 29–42.
  8. Елисеев М. С. Подагра. В кн.: Ревматология. Клинические российские рекомендации. М.: ГЭОТАР-Медиа; 2017: 253–64. [Eliseev M. S. Podagra. V kn.: Revmatologiya. Klinicheskie rossiiskie rekomendatsii. M.: GEOTAR-Media; 2017: 253–64. (in Russian)]
  9. Khanna D., Fitzgerald J., Khanna P., Bae S., Singh M. K., Neogi T. et al. 2012 American College of Rheumatology Guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. (Hoboken). 2012; 64(10): 1431–46.
  10. Jordan K. M., Cameron J. S., Snaith M., Zhang W., Doherty M., Seckl J. et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford). 2007; 46(8): 1372–4.
  11. Stamp L., Merriman T., Barclay M., Singh J. A., Roberts R. L., Wright D. F. et al. Impaired response or insufficient dosage? Examining the potential causes of "inadequate response" to allopurinol in the treatment of gout. Semin. Arthritis Rheum. 2014; 44(2): 170–4.
  12. Fam A. G., Dunne S. M., Iazzetta J., Paton T. W. Efficacy and safety of desensitization to allopurinol following cutaneous reaction. Arthritis Rheum. 2001; 44(1): 231–8.
  13. Sarawate C. A., Patel P. A., Schumacher H. R., Yang W., Brewer K. K., Bakst A. W. Serum urate levels and gout flares: analysis from managed care data. J. Clin. Rheumatol. 2006; 12(2): 61–5.
  14. Borstad G. C., Bryant L. R., Abel M. P., Scroggie D. A., Harris M. D., Alloway J. A. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J. Rheumatol. 2004; 31(12): 2429–32.
  15. Becker M. A., Schumacher H. Jr., Wortmann R. L., MacDonald P. A., Eustace D., Palo W. A. et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N. Engl. J. Med. 2005; 353(23): 2450–61.
  16. Coburn B. W., Bendlin K. A., Sayles H., Meza J., Russell C. L., Mikuls T. R. Allopurinol medication adherence as a mediator of optimal outcomes in gout management. J. Clin. Rheumatol. 2017; 23(6): 317–23.
  17. Елисеев М. С., Желябина О. В., Мукагова М. В., Насонов Е. Л. Клинический опыт применения блокатора интерлейкина 1 канакинумаба у больных хронической тофусной подагрой: купирование артрита и профилактика обострений при назначении аллопуринола. Соврем. ревматология. 2015; 9(2): 16–22. [Eliseev M. S., Zhelyabina O. V., Mukagova M. V., Nasonov E. L. Klinicheskii opyt primeneniya blokatora interleikina 1 kanakinumaba u bol’nykh khronicheskoi tofusnoi podagroi: kupirovanie artrita i profilaktika obostrenii pri naznachenii allopurinola. Sovrem. revmatologiya. 2015; 9(2): 16–22. (in Russian)]
  18. Елисеев М. С., Желябина О. В., Барскова В. Г., Насонов Е. Л. Опыт применения ингибитора интерлейкина 1 канакинумаба у больного с хронической тофусной подагрой. Науч.-практ. ревматология. 2014; 52(1): 99–101. [Eliseev M. S., Zhelyabina O. V., Barskova V. G., Nasonov E. L. Opyt primeneniya ingibitora interleikina 1 kanakinumaba u bol’nogo s khronicheskoi tofus--noi podagroi. Nauch.-prakt. revmatologiya. 2014; 52(1): 99–101. (in Russian)]
  19. MacIsaac R. L., Salatzki J., Higgins P., Walters M. R., Padmanabhan S.,Dominiczak A. F. et al. Allopurinol and cardiovascular outcomes in adults with hypertension. Hypertension. 2016; 67(3): 535–40.
  20. Ng K. P., Stringer S. J., Jesky M. D., Yadav P., Athwal R., Dutton M. et al. Allopurinol is an independent determinant of improved arterial stiffness in chronic kidney disease: a cross-sectional study. PLoS One. 2014; 9(3): e91961.
  21. Dalbeth N., Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin. Dial. 2007; 20(5): 391–5.
  22. Golmohammadi S., Almasi A., Manouchehri M., Omrani H. R., Zandkarimi M. R. Allopurinol against progression of chronic kidney disease. Iran J. Kidney Dis. 2017; 11(4): 286–93.
  23. Yun J., Mattsson J., Schnyder K., Fontana S., Largiadèr C. R., Pichler W. J. et al. Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response. Clin. Exp. Allergy. 2013; 43(11): 1246–55.
  24. Ryu H., Song R., Kim H., Kim J. H., Lee E. Y., Lee Y. J. et al. Clinical risk factors for adverse events in allopurinol users. J. Clin. Pharmacol. 2013; 53(2): 211–6.
  25. Stamp L. K., Day R. O., Yun J. Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Nat. Rev. Rheum. 2016; 12(4): 235–42.
  26. Stamp L. K., Chapman P. T., Barclay M., Horne A., Frampton C., Tan P. et al. Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study. Ann. Rheum. Dis. 2017; PII: annrheumdis-2017-211873
  27. Stamp L., Taylor W., Jones P., Dockerty J. L., Drake J., Frampton C. et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012; 64(8): 2529–36.
  28. Rutherford E., Stewart G., Houston J. G., Jardine A. G., Mark P. B., Struthers A. D. An open-label dose-finding study of allopurinol to target defined reduction in urate levels in hemodialysis patients. J. Clin. Pharmacol. 2017; [Epub ahead of print].
  29. Golmohammadi S., Almasi A., Manouchehri M., Omrani H. R., Zandkarimi M. R. Allopurinol against progression of chronic kidney disease. Iran J. Kidney Dis. 2017; 11(4): 286–93.
  30. Becker M., Schumacher H. Jr., Wortmann R., MacDonald P. A., Palo W. A., Eustace D. et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, phase II, randomized, double-blind, placebo-controlled, doseresponse clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005; 52(3): 916–23.
  31. Schumacher H., Becker M., Wortmann R., Macdonald P. A., Hunt B., Streit J. et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemiaand gout: a 28-week, phase III, randomized, doubleblind, parallel-group trial. Arthritis Rheum. 2008; 59(11): 1540–8.
  32. Faruque L. I., Ehteshami-Afshar A., Wiebe N., Tjosvold L., Homik J., Tonelli M. A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. Semin. Arthritis Rheum. 2013; 43(3): 367–75.
  33. Dalbeth N., Bardin T., Doherty M., Lioté F., Richette P., Saag K. G. et al. Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). Nat. Rev. Rheumatol. 2017; 13(9): 561–8.
  34. Chowalloor P. V., Keen H. I. A systematic review of ultrasonography in gout and asymptomatic hyperuricaemia. Ann. Rheum. Dis. 2013; 72(5): 638–45.
  35. Puig J. G., de Miguel E., Castillo M. C., Rocha A. L., Martínez M. A., Torres R. J. Asymptomatic hyperuricemia: impact of ultrasonography. Nucleosides Nucleotides Nucleic Acids. 2008; 27(6): 592–5.

News

30 June 00:00
A New Issue of Doctor.Ru Neurology Psychiatry, Vol. 20, No. 5 (2021), Published

Find original articles and reviews covering various aspects of neurology, psychiatry and the interview with Professor Marina Arkadievna Kinkulkina

28 June 00:00
A New Issue of Doctor.Ru Internal Medicine, Vol. 20, No. 4 (2021), Published

Find original articles and reviews covering various aspects of cardiology, gastroenterology, internal medicine and the interview with Professor Elena Zelikovna Golukhova

 

3 May 17:06
A New Issue of Doctor.Ru Pediatrics, Vol. 20, No. 3 (2021), Published

Find original articles and reviews covering various aspects of pediatrics and the interview with Professor Evgeny Grigorievich Furman

3 May 17:06
A New Issue of Doctor.Ru Endocrinology, Vol. 20, No. 2 (2021), Published

Find original articles and reviews covering various aspects of endocrinology and the interview with Professor Valentin Viktorovich Fadeev

16 April 11:57
Igor Evgenievich Khatkov joined the American Surgical Association

Igor Evgenievich Khatkov, Head of A. S. Loginov Moscow Clinical Scientific and Practical Centre, Chief Oncologist in and for Moscow is now an honoured member of the American Surgical Association.

All news